TGFB1 and renal fibrosis: In heart and renal fibrosis, angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers that ameliorate cardiac and renal damage and fibrosis through many pathways such as TGF-β and SMAD pathways (Lambers Heerspink et al., 2013).